

# Cyclosporin-Induced Hypertension

Drug Safety

20, 437-449

DOI: 10.2165/00002018-199920050-00004

Citation Report

#	ARTICLE	IF	CITATIONS
1	Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 499-509.	0.3	12
2	Drugs acting on the immune system. <i>Side Effects of Drugs Annual</i> , 2000, , 391-417.	0.6	8
3	Posttransplantation Hypertension Related to Calcineurin Inhibitors. <i>Liver Transplantation</i> , 2000, 6, 521-530.	1.3	132
4	Antihypertensive therapy often needed by transplant recipients treated with cyclosporin. <i>Drugs and Therapy Perspectives</i> , 2000, 15, 13-16.	0.3	0
5	Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. <i>Cardiovascular Research</i> , 2002, 53, 294-303.	1.8	32
6	Immunosuppression impact on long-term cardiovascular complications after liver transplantation. <i>American Journal of Surgery</i> , 2002, 183, 595-599.	0.9	110
8	Arterial hypertension. <i>Transplantation Proceedings</i> , 2002, 34, 127-129.	0.3	2
9	Cardiovascular risk factors associated with immunosuppression in renal transplantation. <i>Transplantation Reviews</i> , 2002, 16, 1-21.	1.2	18
10	Importance of Proximal Tubular Fluid Output in Regulating Long-Term Urinary Sodium Excretion in Health and Disease. <i>Nephron</i> , 2002, 90, 121-132.	0.9	5
11	Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. <i>Kidney International</i> , 2002, 62, S81-S87.	2.6	40
12	Hydrocortisone has a protective effect on CyclosporinA-induced cardiotoxicity. <i>Journal of Cellular Physiology</i> , 2003, 195, 21-26.	2.0	27
13	Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart. <i>International Immunopharmacology</i> , 2003, 3, 427-433.	1.7	35
14	Cardiac Involvement in Rheumatoid Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 121-143.	0.1	1
15	Amelioration of Cyclosporine Nephrotoxicity by Irbesartan, A Selective AT1Receptor Antagonist. <i>Renal Failure</i> , 2004, 26, 467-477.	0.8	13
16	Cyclosporine A and adverse effects on organs: histochemical studies. <i>Progress in Histochemistry and Cytochemistry</i> , 2004, 39, 85-128.	5.1	144
17	Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 169-172.	1.3	13
18	Cardiac function in children post-orthotopic liver transplantation: Echocardiographic parameters and biochemical markers of subclinical cardiovascular damage. <i>Pediatric Transplantation</i> , 2005, 9, 718-722.	0.5	24
19	Change in Renal Heme Oxygenase Expression in Cyclosporine A-induced Injury. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 105-112.	1.3	26

#	ARTICLE	IF	CITATIONS
20	Cyclosporine A induces vascular fibrosis and heat shock protein expression in rat. <i>International Immunopharmacology</i> , 2005, 5, 169-176.	1.7	11
21	Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. <i>Life Sciences</i> , 2005, 77, 2514-2528.	2.0	14
22	Blunted Vascular Response to Endothelin-A Receptor Blockade in Cyclosporine-Treated Lung Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 665-670.	0.3	7
23	New-Onset Cardiovascular Risk Factors in Lung Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1536-1543.	0.3	61
24	The life-threatening complications of dermatologic therapies. <i>Clinics in Dermatology</i> , 2005, 23, 182-192.	0.8	38
26	Hypertension Curriculum Review Donald G. Vidt, MD, Section Editor. Drug Interactions and Drugs That Affect Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2006, 8, 731-737.	1.0	48
27	Superior Immunomodulatory Effects of Intravenous Immunoglobulins on Human T-cells and Dendritic Cells: Comparison to Calcineurin Inhibitors. <i>Transplantation</i> , 2006, 81, 1725-1734.	0.5	42
28	Ciclosporin Aggravates Tissue Damage in Ischemia Reperfusion-Induced Acute Pancreatitis. <i>Pancreas</i> , 2006, 32, 145-151.	0.5	16
29	Drug-induced systemic hypertension. <i>Adverse Drug Reaction Bulletin</i> , 2006, &NA;, 915-918.	0.6	2
30	Dual Effect of Nitrate Therapy for Cyclosporine-Induced Hypertension on Vascular and Platelet Morphofunctional Markers; An Animal Model. <i>Transplantation Proceedings</i> , 2007, 39, 2501-2506.	0.3	5
31	Oxidative Stress in Cyclosporine-Induced Hypertension: Evidence of Beneficial Effects or Tolerance Development With Nitrate Therapy. <i>Transplantation Proceedings</i> , 2007, 39, 2494-2500.	0.3	15
32	Heart disease in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 347-354.	0.6	144
33	Severe Left Ventricular Hypertrophy 1 Year After Transplant Predicts Mortality in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 145-151.	0.3	42
34	Drug-Induced Cardiovascular Disorders. <i>Drug Safety</i> , 2007, 30, 783-804.	1.4	32
35	Increased Vascular Resistance and Not Salt Retention Characterizes Cyclosporine A-Induced Hypertension: Report in an Anuric Patient. <i>American Journal of Transplantation</i> , 2007, 7, 2042-2046.	2.6	9
36	Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children. <i>Pediatric Nephrology</i> , 2008, 23, 1795-1802.	0.9	20
37	Cardioprotective Effects of <i>Nigella sativa</i> Oil on Cyclosporine A-Induced Cardiotoxicity in Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 574-580.	1.2	67
38	Hypertension in rheumatoid arthritis. <i>Rheumatology</i> , 2008, 47, 1286-1298.	0.9	239

#	ARTICLE	IF	CITATIONS
39	PP2B-dependent NO production in the medullary thick ascending limb during diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F471-F480.	1.3	22
40	Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 798-802.	1.3	4
41	Prevalence of myocardial infarction in patients with psoriasis in central China. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1311-1315.	1.3	70
42	Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1100-1107.	2.0	99
43	Hypertension Induced by Immunosuppressive Drugs: A Comparative Analysis Between Sirolimus and Cyclosporine. <i>Transplantation Proceedings</i> , 2009, 41, 868-873.	0.3	37
44	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 451-485.	0.6	505
45	Hypertension after pediatric cardiac transplantation: Detection, etiology, implications and management. <i>Pediatric Transplantation</i> , 2010, 14, 159-168.	0.5	12
46	Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients. <i>Annals of Dermatology</i> , 2010, 22, 300.	0.3	40
47	Management of Corneal Graft Rejection – A Case Series Report and Review of the Literature. <i>Journal of Clinical &amp; Experimental Ophthalmology</i> , 2010, 01, .	0.1	14
48	What Causes a Broken Heart? Molecular Insights into Heart Failure. <i>International Review of Cell and Molecular Biology</i> , 2010, 284, 113-179.	1.6	67
49	Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 838-853.	0.6	86
50	Can early treatment with biologicals modify the natural history of comorbidities?. <i>Dermatologic Therapy</i> , 2010, 23, 181-193.	0.8	23
51	Arterial Hypertension in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2011, 43, 3029-3034.	0.3	24
52	Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). <i>Transplantation</i> , 2011, 91, 976-983.	0.5	148
53	Drugs that increase blood pressure. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 275-282.	0.2	6
54	Spontaneous regression of initially elevated peak systolic velocity in renal transplant artery. <i>Transplant International</i> , 2011, 24, 555-559.	0.8	6
56	Study of the relationship between immunosuppressive therapy and CYP3A4 activity in liver transplantations. <i>Egyptian Liver Journal</i> , 2011, 1, 87-96.	0.3	0
58	Integrated Approach to Comorbidity in Patients With Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2012, 103, 1-64.	0.2	8

#	ARTICLE	IF	CITATIONS
59	Endocrine-Metabolic Pathophysiologic Conditions and Treatment Approaches After Kidney Transplantation. <i>Endocrine Practice</i> , 2012, 18, 579-590.	1.1	3
60	The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients. , 0, , .		0
61	Hydrocortisone attenuates cyclosporin A-induced nephrotoxicity in rats. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 997-1004.	1.2	8
62	Left ventricle geometry remodeling after heart transplantation: A two-dimensional ultrasound study. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2013, 33, 892-896.	1.0	1
63	Long-Term Exposure to Belatacept in Recipients of Extended Criteria Donor Kidneys. <i>American Journal of Transplantation</i> , 2013, 13, 2884-2891.	2.6	66
64	Early development of metabolic syndrome in patients subjected to lung transplantation. <i>Clinical Transplantation</i> , 2013, 27, E237-43.	0.8	21
65	Drug-Induced Cardiovascular Adverse Events in the Intensive Care Unit. <i>Critical Care Nursing Quarterly</i> , 2013, 36, 323-334.	0.4	7
66	Transplant Hypertension. , 2013, , 280-285.		0
67	Mitochondrial injury and dysfunction in hypertension-induced cardiac damage. <i>European Heart Journal</i> , 2014, 35, 3258-3266.	1.0	61
68	Targeting the immune system to treat hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 473-479.	1.0	20
69	Protective effect of curcumin on cyclosporin A-induced endothelial dysfunction, antioxidant capacity, and oxidative damage. <i>Toxicology and Industrial Health</i> , 2014, 30, 316-327.	0.6	20
70	Accidental Overdose of Oral Cyclosporine in Haematopoietic Stem Cell Transplantation: A Case Report and Literature Review. <i>Drug Safety - Case Reports</i> , 2015, 2, 20.	0.9	7
71	The effect of cyclosporine A in hemorrhagic shock model of rats. <i>Journal of Trauma and Acute Care Surgery</i> , 2015, 78, 370-377.	1.1	8
72	Prevention of Nephrotoxicity Induced by Cyclosporine: Role of Antioxidants. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 364-369.	1.2	36
73	Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2015, 253, 1111-1119.	1.0	13
74	Central modulation of cyclosporine-induced hypertension. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 351-361.	1.4	22
75	Ischemic cardiovascular involvement in psoriasis: A systematic review. <i>International Journal of Cardiology</i> , 2015, 178, 191-199.	0.8	26
77	Cyclosporine. , 2016, , 63-73.		0

#	ARTICLE	IF	CITATIONS
78	High Frequency of Arterial Hypertension in Patients After Liver Transplantation. Transplantation Proceedings, 2016, 48, 1721-1724.	0.3	13
79	Angiotensin type-2 (AT-2)-receptor activation reduces renal fibrosis in cyclosporine nephropathy: evidence for blood pressure independent effect. Bioscience Reports, 2016, 36, .	1.1	15
80	Synthetic pharmacotherapy for lupus nephritis. Expert Opinion on Pharmacotherapy, 2017, 18, 175-186.	0.9	4
81	Long-term immunosuppressive therapy for inflammatory eye disease – the link between systemic treatment, cardiovascular risk and disease?. Expert Review of Ophthalmology, 2017, 12, 321-330.	0.3	1
82	Systemic Therapies in Psoriasis. , 2018, , 145-158.		0
83	Cardiovascular and renal interactions between cyclosporine and NSAIDs: Underlying mechanisms and clinical relevance. Pharmacological Research, 2018, 129, 251-261.	3.1	17
84	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 2018, 71, e127-e248.	1.2	4,042
85	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 2018, 71, e13-e115.	1.3	3,332
86	Cyclophilin A as a target in the treatment of cytomegalovirus infections. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661881141.	0.3	8
87	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 138, e484-e594.	1.6	330
88	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	1.5	1,047
89	Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrology Dialysis Transplantation, 2019, 34, 760-773.	0.4	115
90	Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice. Dermatologic Therapy, 2019, 32, e12875.	0.8	7
91	Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial. Transplantation, 2019, 103, 781-788.	0.5	7
92	Iatrogenic hypertension: a bioinformatic analysis. Pharmacogenomics Journal, 2019, 19, 337-346.	0.9	4
93	Cyclosporine Metabolites™ Metabolic Ratios May Be Markers of Cardiovascular Disease in Kidney Transplant Recipients Treated with Cyclosporine A-Based Immunosuppression Regimens. Cardiovascular Toxicology, 2019, 19, 255-263.	1.1	5
94	Blood pressure management in patients receiving renal replacement therapy. Hypertension Research, 2021, 44, 7-12.	1.5	2
95	The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer. International Journal of Biological Sciences, 2021, 17, 2548-2560.	2.6	6

#	ARTICLE	IF	CITATIONS
96	Endocrine Complications Following Hematopoietic Cell Transplantation. , 2021, , 623-643.		0
97	Hypertension in Kidney Transplant Recipients: Where Are We Today?. Current Hypertension Reports, 2021, 23, 21.	1.5	5
98	Effects of Chrysophyllum albidum fruit pulp on haemodynamic parameters, pro-inflammatory markers, antioxidant parameters and critical biomolecules associated with hypertensionâ€“in vivo. Inflammopharmacology, 2021, 29, 825-839.	1.9	2
99	Unexpected overdose of oral cyclosporine in a kidney transplant patient: a case report. European Journal of Hospital Pharmacy, 2023, 30, 242-244.	0.5	3
100	Diet Supplemented with Chrysophyllum albidum G. Don (Sapotaceae) Fruit Pulp Improves Reproductive Function in Hypertensive Male Rats. Reproductive Sciences, 2021, , 1.	1.1	4
101	Hypertension Drug Therapy. Advances in Experimental Medicine and Biology, 2020, 1177, 149-268.	0.8	6
102	Cyclosporin-induced hypertension. Journal of Hypertension, 2001, 19, 2283-2285.	0.3	18
103	CYCLOSPORINE AND LONG-TERM KIDNEY GRAFT SURVIVAL. Transplantation, 2001, 72, 1267-1273.	0.5	49
104	Endocrine-Metabolic Pathophysiologic Conditions and Treatment Approaches after Kidney Transplantation. Endocrine Practice, 2012, 18, 579-590.	1.1	2
105	Psoriasis and High Blood Pressure. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2015, 69, 13.	0.4	10
106	Special Situations in the Management of Hypertension. , 2001, , 252-274.		1
107	Miscellaneous therapeutic and diagnostic agents. , 2001, , 556-584.		0
108	Special Situations in the Management of Hypertension. , 2003, , 257-281.		0
109	Refractory Hypertension. , 2004, , 3-20.		0
110	A Comparision of Adverse Effects Profile between Cyclosporine and Tacrolimus in Liver Transplant Recipients. Journal of Korean Society of Health-System Pharmacists, 2008, 25, 1-8.	0.1	0
114	The Transplanted Heart. , 2013, , 149-157.		0
115	Transplant Hypertension. , 2018, , 321-327.		0
116	Antihypertensives in dermatology Part I - Uses of antihypertensives in dermatology. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 6.	0.2	3

#	ARTICLE	IF	CITATIONS
117	Neuroanesthesia and Coexisting Transplanted Organs. , 2019, , 253-275.		0
118	Current features of management of comorbid patients with hypertension. Medical Alphabet, 2019, 2, 6-11.	0.0	2
119	Revisiting the transplantation of donor heart with left ventricular myocardial hypertrophy. Transplantologia, 2020, 12, 42-48.	0.1	1
120	Traditional systemic therapy I: methotrexate and cyclosporine. , 2008, , 103-120.		3
121	Summary of Published Treatment Guidelines. , 2021, , 399-414.		0
122	Antihypertensive agents and renal transplantation. Hippokratia, 2007, 11, 3-12.	0.3	50
123	A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Iranian Journal of Pharmaceutical Research, 2016, 15, 331-9.	0.3	2
124	Calcineurin Controls Hypothalamic NMDA Receptor Activity and Sympathetic Outflow. Circulation Research, 2022, 131, 345-360.	2.0	11
125	Acute effect of nitroglycerin on cyclosporine-induced hypertension after cardiac transplantation. Swiss Medical Weekly, 0, , .	0.8	1